Distress

Regen Biopharma, with $239 in cash at June 30, signs $125,000 note and $10 million equity line with Coventry

RGBP

Most of what the note paid out went to retire $71,557 of older convertible debt. The equity line sells stock at 80% of the lowest recent price and cannot start until an S-1 is effective.

Investor Chat

Scorecard

RGBP
Investor Impact: 9/10, Very highHow important this specific story was to investors when we published it, whether the news was good or bad. · High evidence · As of 2026-11-05
Very highHigh evidence
Investment Attractiveness: 3.9/10, MixedThe company’s relative investment appeal, based on financial strength, valuation and execution. · Relative financial and execution position; not a forecast of stock returns. · As of 2026-11-05
Mixed
Company Deal Record: 5/10, Mixed recordHow favorable the company’s past financings have been, with more weight on recent deals. · As of 2026-11-05
Mixed record

By the aibio.space news desk

Chairs around a table in a meeting room
Chairs around a table in a meeting room. Photo: Breather breather, CC0, via Wikimedia Commons. The picture shows the field, not the companies named.

Regen Biopharma, Inc. (OTC: RGBP) signed two financing agreements with Coventry Enterprises, LLC on October 27, 2026. One is a $125,000 unsecured note. The other is an equity line under which Coventry is committed to buy up to $10,000,000 of common stock over 36 months. Chief Executive Officer David Koos signed the agreements and the November 2 Form 8-K. Regen's last quarterly report showed $239 of cash at June 30, 2026, a stockholders' deficit of $5,878,206 and substantial doubt about its ability to continue as a going concern. Both new deals are priced off the lowest recent trading price, so existing holders take the hit if the stock falls. Form 8-K, November 2

What the note costs

Coventry kept $12,500 of the $125,000 principal as original issue discount, so Regen received at most $112,500. Of that, $71,557 paid off existing convertible debt and accrued interest. At most $40,943 was left before any expenses, and the filing does not say how much the company actually kept. The note carries "Guaranteed Interest" of $12,500 over its eighteen-month term. Regen pays eight monthly installments of $17,187.50, or $137,500 in all, starting six months after funding and due on the 20th of each month. Form 8-K

The note can be prepaid without penalty. After a default, default-rate interest accrues, and Coventry can demand a Mandatory Default Amount of 120% of outstanding principal plus accrued interest, in cash or in stock. Note, Exhibit 10.2

When the note turns into stock

The note converts on an Event of Default, at Coventry's option, at 90% of the lowest trading price in the 20 trading days before conversion. That price floats, so the weaker the stock, the more shares Coventry gets. There is a second route that needs no default. If the note has been outstanding for four months and Regen closes another financing, or has an effective Regulation A offering statement, Coventry may convert the whole balance, guaranteed interest included, at that offering's price. Form 8-K

What the equity line allows

Coventry does not have to buy anything until a Form S-1 covering its resale becomes effective. After that, Regen picks the timing with each Draw Down Notice. Coventry pays 80% of the lowest trading price in the ten business days before the notice. Each draw is capped at the lesser of 200% of average daily traded value over those ten days or $250,000. No draw may lift Coventry above 4.99% of the outstanding shares. At the $250,000 cap, the full $10,000,000 would take at least 40 draws. Form 8-K

The filings name no placement agent, underwriter, financial advisor or counsel. In the equity line agreement, Regen states it has taken no action that would give rise to any broker's commission. Jack Bodenstein signed for Coventry as Managing Member. Equity line, Exhibit 10.3

The balance sheet behind it

At June 30, 2026, Regen had $287,587 of total assets against $6,165,793 of current liabilities. Those liabilities included a $1,901,963 derivative liability and $726,291 of convertible notes net of discount. For the nine months to June 30 the company had an operating loss of $680,805 and used $285,244 of cash in operations. Revenue was $177,194, of which $82,274 came from a related party. Weighted average shares in the June quarter were 615,555,666, up from 23,752,506 a year earlier. The company also issued twenty million shares to its Chief Executive Officer for services tied to a planned Phase I trial of HemaXellerate. It says it is looking for small molecules that act on NR2F6. Form 10-Q, June 30

Regen filed a notice of late filing for that quarter on August 13 and filed the 10-Q on August 17. EDGAR filing index

In our reading, a $125,000 note that mostly repays older lenders does little for a company with $239 in the bank and more than $6 million of current liabilities. Real money can only come from the equity line, and only after an S-1 is effective, at a 20% discount to the lowest recent price. The filing gives no current cash figure. The next documents to watch are that S-1 and the annual report for the year to September 30, 2026, which should show what the note left behind.

Investor Chat

Loading posts…

Settings

Text size
Motion

Stops the moving share lists on the front page.

Your choices are saved in this browser only.

Free membership

Get aibio.space by email, free

Get updates from aibio.space by email. Sign up with your email address to receive updates and offers. Unsubscribe in one click.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address.